Fructose Breath-testing in Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome Clinical Trial

Official title:

Assessment of Psychological and Metabolic Responses During Fructose Intolerance Breath Tests in Patients With Functional GI Disorders: Placebo-controlled Breath Testing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02614313
• Other study ID #: BGRG FBT-PLA
• Status: Completed
• Phase: N/A
• Start date: June 2016
• Est. completion date: August 2017

Study information

• Verified date: December 2018
• Source: Brain-Gut Research Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Background: Breath testing for food intolerances is becoming routine in patients with functional gastrointestinal disorders (FGID). Both FGID and saccharide intolerances (FODMAPs: fermentable oligo-, di-, polysaccharide and polyols, e.g. lactose, fructose, sorbitol) are common (>10% of any given population) and often respond to dietary modification. The breath tests are based on quantification of gas excretion in breath as a sign of malabsorption and symptom provocation, but are likely subject to considerable psychological bias. The role of expectation and other psychological effects on breath testing has not been reported, but is crucial for the validation of these increasingly wide-spread tests with considerable dietary and potentially deleterious consequences. Fructose has been shown to result in short term pro-inflammatory metabolic responses, but these effects have not been studied as underlying causes for intolerance symptoms in fructose intolerant patients with FGID.

Aim: To investigate the psychological component and the short-term metabolic effects of fructose breath testing in patients referred for evaluation of FGID using placebo. Additionally, to assess baseline predictors for a positive breath test result.

Methods: Fructose intolerance (defined by a positive symptom index) and malabsorption (defined by increased breath hydrogen/methane concentrations) will be determined in 30 successive male and female FGID in a single centre using breath-testing. Fructose 35g, given double-blind as well as open, a sweet placebo (cyclamate/saccharine; Assugrin®) and a neutral (still water) placebo given double-blind will be compared in a randomized, cross-over sequence and according to our standardised procedure on four separate study days. Symptoms will be recorded using standardised questionnaires and breath concentrations of H2 and CH4 will be measured during testing on the four study days. Somatisation and psychological profiles will be assessed by questionnaires. Blood samples will be obtained before and during provocation testing to assess short-term responses to fructose loading by metabolomics. Fructose, blinded and open, and placebo responses will be compared and baseline predictors for a positive breath tests assessed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: August 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion criteria

• Thirty male or female FGID (Irritable Bowel Syndrome or Functional Dyspepsia according to the Rome III criteria) patients -

• 10 healthy female and male controls

• aged between 18 and 60 years

Exclusion criteria:

• Bowel resections, except appendicectomy or cholecystectomy

• Evidence of organic disease

• No medications (excluding antihypertensives, antidepressants and low-dose aspirin), including herbal, from 4 days before the first study day until after breath test

• Coeliac's disease

Related Conditions & MeSH terms

• Digestive System Diseases
• Functional Gastrointestinal Disorders
• Gastrointestinal Diseases
• Irritable Bowel Syndrome
• Syndrome

Intervention

Procedure:
• Open breath test with fructose
Open randomised fructose 35g during breath test
• Breath test with sweet placebo (Assugrin)
Double-blind randomised breath-testing with sweet placebo (Assugrin)
• Breath test with neutral placebo (still water)
Double-blind randomised breath-testing with neutral placebo
• Blinded breath test with fructose
Double-blind randomised fructose 35g during breath test

Locations

Country	Name	City	State
Switzerland	Gastoenterology Group Practice	Bern

Sponsors (3)

Lead Sponsor	Collaborator
Brain-Gut Research Group	National University, Singapore, New Jersey Medical School

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fructose intolerance, as percentage of patients	Defined by symptom scores	5 hours
Secondary	Between-group comparisons of breath test gas concentrations and symptom indices	Breath gas concentrations and cumulative symptoms experienced during breath testing will be compared between treatment groups	5 hours
Secondary	Correlations between breath test gas concentrations, symptom indices and metabolite	Correlations between changes in gas levels, GI symptoms from baseline and changes in metabolites identified by metabolomic analysis in the different treatment and responder groups (i.e intolerance or no intolerance as defined by the standard breath test results). Metabotype and psychological predictors at baseline for intolerance (responder) status during breath testing will be assessed by multiple regression analysis.	5 hours